N5770
Nalmefene
别名:
(5α)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol
表单
solid
创始人
Baxter
储存温度
2-8°C
SMILES字符串
Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O)CC6CC6
InChI
1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
InChI key
WJBLNOPPDWQMCH-MBPVOVBZSA-N
基因信息
human ... OPRD1(4985), OPRK1(4986), OPRM1(4988)
rat ... Oprd1(24613), Oprm1(25601)
生化/生理作用
Nonselective opioid receptor antagonist.
特点和优势
This compound was developed by Baxter. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - Aquatic Chronic 1 - STOT SE 3
靶器官
Central nervous system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
Jon E Grant et al.
Psychopharmacology, 200(4), 521-527 (2008-06-27)
Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms
Stephani A Day et al.
Biochemical pharmacology, 81(8), 996-1003 (2011-02-05)
Hepatic fibrosis is characterized by excess type I collagen deposition and exacerbated inflammatory response. Naltrexone, an opioid receptor antagonist used for treating alcohol abuse, attenuates hepatocellular injury in fibrotic animal models, which can be accompanied by deleterious side effects. Additionally
Susanne Rösner et al.
The Cochrane database of systematic reviews, (12)(12), CD001867-CD001867 (2010-12-15)
Alcohol dependence belongs to the globally leading health risk factors. Therapeutic success of psychosocial programs for relapse prevention is moderate and could be increased by an adjuvant treatment with the opioid antagonists naltrexone and nalmefene. To determine the effectiveness and
Trial watch: Nalmefene reduces alcohol use in phase III trial.
Nature reviews. Drug discovery, 10(8), 566-566 (2011-08-02)
Rainer Spanagel et al.
Current topics in behavioral neurosciences, 13, 583-609 (2012-03-06)
Here we discuss treatment strategies that are based on pharmacological interventions to reduce craving and relapse in alcohol-dependent patients. We will first provide a historical overview about relapse prevention strategies. We will then review the development of disulfiram, naltrexone, acamprosate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持